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Abstract
Aims/hypothesis The aim of this study was to assess the
prevalence of (unknown) heart failure and left ventricular
dysfunction in older patients with type 2 diabetes.
Methods In total, 605 patients aged 60 years or over with
type 2 diabetes in the south west of the Netherlands partic-
ipated in this cross-sectional study (response rate 48.7%),
including 24 with a cardiologist-confirmed diagnosis of
heart failure. Between February 2009 and March 2010, the
patients without known heart failure underwent a standar-
dised diagnostic work-up, including medical history, phys-
ical examination, ECG and echocardiography. An expert
panel used the criteria of the European Society of Cardiol-
ogy to diagnose heart failure.
Results Of the 581 patients studied, 161 (27.7%; 95% CI
24.1%, 31.4%) were found to have previously unknown
heart failure: 28 (4.8%; 95% CI 3.1%, 6.6%) with reduced
ejection fraction, and 133 (22.9%; 95% CI 19.5%, 26.3%)
with preserved ejection fraction. The prevalence of heart
failure increased steeply with age. Heart failure with preserved
ejection fraction was more common in women. Left ventric-
ular dysfunction was diagnosed in 150 patients (25.8%; 95%
CI 22.3%, 29.4%); 146 (25.1%; 95% CI 21.6%, 28.7%) had
diastolic dysfunction.
Conclusions/interpretation This is the first epidemiological
study that provides exact prevalence estimates of (previously
unknown) heart failure and left ventricular dysfunction in a
representative sample of patients with type 2 diabetes. Previ-
ously unknown heart failure and left ventricular dysfunction
are highly prevalent. Physicians should pay special attention
to ‘unmasking’ these patients.
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Cardiovascular diseases are of major importance in patients
with type 2 diabetes, accounting for up to 80% of the excess
mortality in these patients [1]. Processes underlying the excess
cardiovascular mortality risk include coronary atherosclerosis,
generalised microvascular disease and autonomic neuropathy
[1]. In addition, myocardial abnormalities (‘diabetic cardio-
myopathy’) and heart failure seem to play a role [2, 3]. In
general, underdiagnosis of heart failure is common [4]; a
prevalence of unrecognised heart failure of up to 20.5% has
been reported in specific patient groups, such as patients with
chronic obstructive pulmonary disease [4, 5]. Previously
reported heart failure prevalence estimates in patients with
type 2 diabetes were based on medical records or heart failure
scores, lacking echocardiography in all patients. Reported
prevalence ranged from 9.5% to 22.3% [6–9], and the inci-
dence of heart failure in patients with type 2 diabetes was
about 2.5 times that in people without diabetes [10]. In one
study, echocardiography was used to diagnose heart failure
with reduced ejection fraction (HFREF), resulting in a preva-
lence of 7.7%, but diastolic dysfunction and heart failure with
preserved ejection fraction (HFPEF) was not assessed [11].
To our knowledge, exact prevalence estimates of (unrec-
ognised) heart failure, with and without reduced ejection
fraction, and systolic and diastolic dysfunction in a repre-
sentative sample of all older patients with type 2 diabetes are
lacking. We therefore assessed this prevalence in patients
aged 60 years and older with type 2 diabetes, all undergoing
echocardiography.
Methods
Participants The study was conducted between February
2009 and March 2010, in the province of Zeeland, in the
south west of the Netherlands. We were able to invite a
representative group of patients with type 2 diabetes, at least
for Western Europe, because all patients with type 2 diabetes
in this region are enrolled in the Diabetes Care programme
of the Center for Diagnostic Support in Primary Care (SHL),
including those (co-)treated by hospital specialists (~50,000
patients during the period of this study). Of all the patients
with type 2 diabetes from the participating physicians in this
study, 1,243 were 60 years or older, and were invited.
All participants gave written informed consent, and the
institutional review board of the University Medical Center
Utrecht and the Admiraal de Ruyter Hospital in Goes, the
Netherlands approved the study protocol. The protocol of
the study has been published previously [12] and the study
is registered at www.ccmo.nl, NL2271704108.
Measurements The patients without a cardiologist-confirmed
diagnosis of heart failure (i.e. including echocardiographic
evidence of left ventricular dysfunction) underwent a stand-
ardised diagnostic assessment, which was executed in the
cardiology outpatient department of the Admiraal de Ruyter
Hospital in Goes. Information on duration of diabetes, smok-
ing habits and comorbidities was obtained from the patients
and the registry. Patients were asked to bring their medication
packages so that current drug treatment could be checked. The
presence of angina pectoris and shortness of breath was
assessed with the WHO questionnaires [13]. Symptoms and
signs were assessed by a trained physician in a standardised
manner. A standard 12-lead ECG was recorded and classified
according to the Minnesota coding criteria by a single expe-
rienced cardiologist, blinded to all other test results. Systolic
and diastolic blood pressure was measured once electronical-
ly, after 5 min of rest in a supine position. Blood was taken
within 2 weeks of the diagnostic assessment, with measure-
ment of serum B-type natriuretic peptide (NT-proBNP), blood
glucose, creatinine and HbA1c. NT-proBNP was measured
with a non-competitive immunoradiometric assay (Roche
Diagnostics, Mannheim, Germany).
Echocardiography was performed with a General Electric,
Vivid 7 imaging system device (GE Vingmed Ultrasound AS,
Horten, Norway) by well-trained and experienced cardiac
sonographers. Variables from Doppler analysis, M-mode
echocardiography and two-dimensional transthoracic echo-
cardiography were used. Where image quality was adequate,
left-ventricular ejection fraction (LVEF) was calculated from
the endocardial surface tracings in the apical four-chamber
view and two-chamber view, using Simpson’s rule (disc sum-
mation method) [14, 15].
LVEF could be assessed in 97.5% of the patients by a
quantitative method or the two-dimensional visual estimate
method (‘eyeballing’) [16]. The accuracy of eyeballing has
been validated previously [17]. Wall motion abnormalities
were visually analysed and summarised in a wall motion
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score [18]. Left ventricular mass was calculated usingM-mode
measurements and the formula of Devereux and Reichek [19].
Valve regurgitation was graded semi-quantitatively, and, in the
case of aortic stenosis, the pressure gradient was measured.
Left atrial (LA) volume was assessed by the biplane area–
length method from apical four- and two-chamber views
[20]. Indexed values were corrected for body surface
area. The cut-off values 28 and 34ml/m2 were used for normal
and definitely increased LA volume index, respectively
[21].
Mitral inflow and pulmonary venous inflow were assessed
by means of pulsed-wave Doppler echocardiography. From
the mitral inflow profile, the early diastolic mitral flow veloc-
ity (E) and atrial contraction (A)-wave velocity and the E-
deceleration time were measured, and the early-to-atrial left
ventricular filling ratio (E/A) was calculated. The flow veloc-
ities of the left or right upper pulmonary vein were recorded,
and the ratio of systolic to diastolic forward flow (S/D) was
calculated. We measured the peak velocity of the tricuspid
regurgitated signal with continuous-wave Doppler and calcu-
lated the systolic pulmonary artery pressure with the modified
Bernoulli’s equation [22].
Diastolic function was assessed by an approach that
integrates Doppler measurements of the mitral inflow and
Doppler tissue imaging of the mitral annulus using the early
diastolic septal annular velocity (e’) [23]. E’(early diastolic
mitral annular velocity) is a measure of the relaxation of the
ventricle. We calculated the early filling to early diastolic
mitral annular velocity ratio (E/e') as a measure of filling
pressures [24].
Criteria to establish diastolic and systolic dysfunction and
heart failure An E/e' value below 8 was considered normal,
and 8–15 indeterminate. An E/e'≥15 was considered abnor-
mal [25], and these patients were classified as having dia-
stolic dysfunction. When E/e' was between 8 and 15 and a
septal e' <8 cm/s, a combination of elevated values of the
indexed volume of the left atrium, the mitral inflow and
pulmonary venous flow were used to classify the presence
or absence of diastolic dysfunction. Diastolic function was
categorised as normal, impaired relaxation (grade I), pseudo
normal filling (grade II) or restrictive filling (grade III) by a
combination of age-corrected values of E/A velocity ratio,
the E-deceleration time, and S/D (see Table 1) [26]. Patients
with E/e' between 8 and 15 and a septal e' <8 cm/s, who had
echocardiographic left ventricular hypertrophy or elevated
indexed LAvolume or S/D<1 were also classified as having
diastolic dysfunction. In patients with atrial fibrillation, we
considered an elevated indexed LA volume sufficient to
classify as diastolic dysfunction.
Systolic dysfunction was defined as an LVEF≤45% by
echocardiography, and diastolic dysfunction graded as I, II
or III in combination with an LVEF>45%.
To be classified as heart failure, systolic or diastolic
dysfunction had to be present in combination with one or
more suggestive symptoms (e.g. orthopnoea, paroxysmal
nocturnal dyspnoea, fatigue, peripheral oedema, nocturia
more than twice a night) and one or more signs indicative
of heart failure (e.g. peripheral or pulmonary fluid retention
or raised jugular venous pressure). In patients who used
diuretics, signs of volume overload were not obligatory to
classify the presence of heart failure.
Presence or absence of dysfunction and heart failure was
determined by an expert panel consisting of two cardiolo-
gists (MJC and MJL) and one general practitioner with
special interest in heart failure (FHR). The panel was guided
by the diagnostic principles of the most recent guidelines for
heart failure of the European Society of Cardiology (ESC)
[27]. All available results from the diagnostic assessment
except for the NT-proBNP results were used. This was done
because we wanted to assess the diagnostic value of NT-
proBNP separately. The expert panel also established the
most likely cause of heart failure based on the diagnostic
assessment, including ECG and echocardiography. In the
case of no consensus, the majority decision was used.
A random sample of 63 (10.7%) patients was reclassified
by the expert panel blinded to the original classification. In
five cases, the diagnosis ‘presence or absence of heart fail-
ure’ did not correspond to the original diagnosis (κ 0.82, SD
0.08). Incongruent cases most often occurred between dia-
stolic dysfunction and diastolic heart failure.
Data analyses We calculated age- and sex-specific preva-
lence rates of unrecognised HFREF and HFPEF and systolic
and diastolic dysfunction. Overall heart failure prevalence
estimates were calculated by including patients who already
had a cardiologist-confirmed diagnosis of heart failure at
baseline in both the numerator and denominator. Prevalence
estimates are given for 5-year age groups and for men and
women separately. Binominal confidence intervals (95%)
Table 1 Age-corrected Doppler
mitral inflow and pulmonary
flow profiles used to classify
diastolic function
DT, deceleration time






E/A (cm/s) 0.75<E/A<1.5 E/A≤0.75 0.75<E/A<1.5 E/A>1.5
DT (ms) 140<DT<320 ≥180 140<DT<320 DT<140
S/D ≥1 ≥1 <1 <1
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were calculated for overall prevalence rates. Data with a
skewed distribution were summarised as medians with
IQRs. Data were analysed using SPSS Windows version
16.0 for Windows (SPSS, Chicago, IL, USA).
Results
Participants In total, 605 patients agreed to participate (re-
sponse rate 48.7%), 581 of them without a cardiologist-
confirmed diagnosis of heart failure. The mean age of the
605 responders was 71.5 (SD 7.5) years, and 54.0% (95% CI
50.1%, 58.0%) were male. The mean HbA1c was 6.7% (SD
0.5%) (49.0 [SD 6.1] mmol/mol), creatinine 81.7 (SD 15.9)
μmol/l, andmodification of diet in renal disease (MDRD) 82.8
(SD 15.4) ml min−1 1.73m−2. Themean age of non-responders
was 77.0 (SD 9.1) years, the percentage of men 43.4 (95% CI
39.6, 47.3), HbA1c 6.7% (SD 0.6%) (49.4 [SD 6.8] mmol/mol),
creatinine 84.5 (SD 19.7) μmol/l and MDRD 79.0 (SD 17.9)
ml min−1 1.73 m−2. Table 2 shows the characteristics of the
participants previously not known to have heart failure.
Prevalence of heart failure Of the 581 patients previously
not known to have heart failure, 161 were diagnosed with
heart failure (prevalence 27.7%; 95% CI 24.1%, 31.4%): 28
(4.8%; 95% CI 3.1%, 6.6%) with HFREF, 133 (22.9% 95%
CI 19.5%, 26.3%) with HFPEF, and none with right-sided
heart failure. Of those with HFREF, nine had an LVEF≤
40%, and 19 an LVEF between 40% and 45%. The overall
prevalence of heart failure among the 605 patients was 185
(30.6%; 95% CI 26.9%, 34.2%): 35 (5.8%; 95% CI 3.9%,
7.6%) with HFREF, and 150 (24.8%; 95% CI 21.4%,
28.2%) with HFPEF. In addition, five patients were classi-
fied as having possible heart failure by the expert panel: one
with HFREF, three with HFPEF, and one with right-sided
heart failure. Sex-specific prevalence rates for 5-year age
groups of previously unknown HFREF and HFPEF are
shown in Table 3. The prevalence of heart failure increased
with age, and was overall higher in female than male
patients (31.0% vs 24.8%). The prevalence of HFREF was
higher in men (6.8%) than women (3.0%).
Prevalence of heart failure in specific subgroups The prev-
alence was 38.7% (95% CI 31.2%, 46.1%) in patients with a
BMI≥30 kg/m2 and 23.4% (95% CI 19.4%, 27.5%) in those
with a BMI <30 kg/m2. In patients with dyspnoea, the
prevalence was 46.6% (95% CI 40.4%, 52.7%) and 13.3%
(95% CI 9.7%, 17.0%) in those without dyspnoea. In
patients with fatigue, the prevalence was 45.6% (95% CI
39.1%, 52.0%) and in those without fatigue 16.1% (95% CI
12.3%, 20.0%). In patients treated for hypertension, the
prevalence was 31.2% (95% CI 26.6%, 35.9%) and in those
not treated for hypertension 21% (95% CI 15.4%, 26.6%).
Prevalence of left ventricular dysfunction In addition, left
ventricular dysfunction was diagnosed in 150 patients
(25.8%; 95% CI 22.3%, 29.4%); nearly all (97.3%) had
diastolic dysfunction. Of the 581 patients, 264 (45.4%)
had ‘normal’ left ventricular function, although 65 (11.2%)
had an LVEF 45–55% (without diastolic dysfunction) and
could be considered to have suboptimal systolic left ventric-
ular function. Prevalence rates for diastolic and systolic
dysfunction are shown in Table 4. The systolic dysfunction
was higher in men (1.3%) than in women (0%).
Causes of heart failure According to the panel, hyperten-
sion with or without left ventricular hypertrophy was the
most common cause (82%) of heart failure, followed by
prior myocardial infarction (23%) and other ischaemic heart
disease (39.8%) (Table 5). If the duration of diabetes was
longer than 5 years, diabetic cardiomyopathy was often
considered to be a possible cause (29.8%). Other common
causes of heart failure according to the panel were atrial
fibrillation (10.6%), valvular disease (23.6%), or any com-
bination of possible causes. Myocardial infarction and other
ischaemic heart disease were more common (46.4% and
50.0%, respectively) in the subgroup with HFREF. Most
patients with heart failure were classified as New York Heart
Association (NYHA) functional class II or III at the time of
investigation (Table 5).
Discussion
Our study in a large representative group of older patients
with type 2 diabetes showed that the prevalence of previ-
ously unknown heart failure is very high (27.7%), steeply
increases with age, and is overall higher in women (31.0%)
than men (24.8%). The prevalence is significantly higher in
patients with a BMI≥30 kg/m2 (38.7% vs 23.4%), in
patients with dyspnoea (46.6% vs 13.3%), in patients com-
plaining of fatigue (45.6% vs 16.1%) and treated for hyper-
tension (31.2% vs 21%). The majority (82.6%) of the
patients with newly detected heart failure had HFPEF (preva-
lence 22.9%). Moreover, the prevalence of left ventricular
dysfunction (25.8%), mainly diastolic dysfunction (25.1%),
was high. Only 264 (45.4%) of all investigated patients had
‘normal’ left ventricular function, including 65 (11.2%) with a
suboptimal LVEF of 45–55%.
The high prevalence of previously unknown heart failure
could be due to patients with symptoms of heart failure not
going to a physician or physicians not asking the patient
about these symptoms. A further possibility is that when
patients do present with these symptoms, physicians do not
recognise heart failure.
Hypertension was presumed to be the most important
possible cause of heart failure in our study population,
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Table 2 Characteristics of patients with type 2 diabetes aged ≥60 years, previously not known to have heart failure, categorised as newly detected








Mean (SD) age (years)a 71.6 (7.4) 74.5 (7.7) 70.5 (6.9) <0.001
Male 310 (53.4) 77 (47.8) 233 (55.5) 0.098
Median (IQR) duration of diabetesa 5.5 (3.0, 15.2) 6.3 (3.3, 10.2) 5.1 (3.0, 10.1) 0.292
Mean (SD) HbA1c (%) 6.7 (0.7) 6.7 (0.7) 6.7 (0.7) 0.519
Mean (SD) HbA1c (mmol/mol) 49.5 (8.0) 49.9 (8.2) 49.4 (7.4) 0.519
Current smoker 80 (13.8) 24 (14.9) 56 (13.3) 0.622
Mean (SD) BMI (kg/m2) 28.1 (5.1) 29.7 (6.0) 27.6 (4.5) <0.001
BMI >30 kg/m2 163 (28.1) 63 (39.1) 100 (23.8) <0.001
Comorbiditiesb
Ischaemic heart diseasec 108 (18.6) 50 (31.1) 58 (13.8) <0.001
Atrial fibrillation 42 (7.2) 20 (12.4) 22 (5.2) 0.003
Stroke/TIA 55 (9.5) 23 (14.3) 32 (7.6) 0.014
Peripheral arterial disease 39 (6.7) 21 (13.0) 18 (4.3) <0.001
Hypertension 381 (65.6) 119 (73.9) 262 (62.4) 0.009
Asthma/COPD 71 (12.2) 28 (17.4) 43 (10.2) 0.018
Renal dysfunction 26 (4.5) 11 (6.8) 15 (3.6) 0.089
Thyroid disease 43 (7.4) 15 (9.3) 28 (6.7) 0.275
Medication
Loop diuretics 36 (6.2) 22 (13.7) 14 (3.3) <0.001
Thiazide diuretics 167 (28.7) 51 (31.7) 116 (27.6) 0.333
ACE-inhibitors/angiotensin receptor blockers 306 (52.7) 102 (63.4) 204 (48.6) <0.001
Aldosterone antagonist 4 (0.7) 1 (0.6) 3 (0.7) 0.903
β-Blockers 209 (36.0) 84 (52.2) 125 (29.8) <0.001
Dihydropyridines 30 (5.2) 14 (8.7) 16 (3.8) 0.017
Non-dihydropyridines 65 (11.2) 26 (16.1) 39 (9.3) 0.019
Metformin 302 (52.0) 91 (56.5) 211 (50.2) 0.175
Sulfonylurea derivatives 213 (36.7) 59 (36.6) 154 (36.7) 0.996
Thiazolidinediones 17 (2.9) 4 (2.5) 14 (3.1) 0.696
Insulin 73 (12.6) 23 (14.3) 50 (11.9) 0.438
Symptoms
Dyspnoea 251 (43.2) 117 (72.7) 134 (31.9) <0.001
Fatigue 228 (39.2) 104 (64.6) 124 (29.5) <0.001
Paroxysmal nocturnal dyspnoea or orthopnoea 61 (10.5) 31 (19.3) 30 (7.1) <0.001
Swollen ankles 161 (27.7) 75 (46.6) 86 (20.5) <0.001
Nocturia 260 (44.8) 94 (58.4) 166 (39.5) <0.001
Angina pectoris 48 (8.3) 24 (14.9) 24 (5.7) <0.001
Palpitations 113 (19.4) 43 (26.7) 70 (16.7) 0.006
Additional tests
Abnormal ECGd 342 (58.9) 128 (79.5) 214 (51.0) <0.001
NT-proBNP ≥15 pmol/l (125 pg/ml) 183 (31.5) 87 (54.0) 96 (22.9) <0.001
Median (IQR) NT-proBNP 9.0 (5,18) 16.0 (9, 41) 8 (5, 14) <0.001
Echocardiographic variables
Mean (SD) LVEF 60.2 (8.2) 56.9 (9.4) 61.4 (7.4) <0.001
LVEF >55% 438 (75.4) 107 (66.5) 331 (78.8) 0.002
LVEF 45–55% 117 (20.1) 34 (21.1) 83 (19.8) 0.430
LVEF ≤45% 26 (4.5) 20 (12.4) 6 (1.4) <0.001
Mean (SD) e' 0.06 (0.02) 0.06 (0.2) 0.07 (0.2) <0.001
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according to the panel. Previous studies have shown that
hypertension generates a high population attributable risk of
heart failure [28] and diastolic left ventricular dysfunction
[29].
The exact reason for the high prevalence of diastolic
dysfunction is not known, although it may be related to
early stages of so-called ‘diabetic cardiomyopathy’ [30].
Our finding that the majority of the patients had an E/A
ratio <1, and 52.3% had an E/A ratio <0.75, supports this
idea. A low E/A ratio has been linked to early stages of
diabetic cardiomyopathy [29, 31].
Several limitations of our study should be discussed. The
relatively high blood pressure values could be the result of
the single measurement used in our study. Importantly, this
had no influence on the prevalence estimates of the cause of
heart failure adjudged by the panel, since the panel used a
history of high blood pressure rather than current blood
pressure levels. NT-proBNP levels were not available to
the panel, to prevent incorporating bias for the diagnostic
part of the study that will be performed. This may have had
some influence on the panel’s diagnosis, although the effect
is likely to be small because, in all participants, a complete
echocardiographic assessment, including tissue Doppler im-
aging measurements, was available. When evaluating the
possible causes of heart failure, it is important to consider
that the panel judged ‘likely’ causes on the basis of the
diagnostic assessment, but without specific and detailed
further investigations. Under-rating the importance of is-
chaemia as the possible cause of heart failure is therefore
likely.
One of the strengths of the study is a relatively high
response rate (48.7%) compared with other population-
based studies involving extensive diagnostic testing [5].
As can be expected, the non-responders were older and
probably more fragile than the participants. This may have
led to a limited underestimation of the prevalence. Impor-
tantly, the clinical applicability of our results is high, be-
cause we studied patients who were able and willing to
undergo the relevant diagnostic investigations, as in every









Mean (SD) E/e' 9.5 (3.4) 11.4 (5.0) 8.8 (2.3) <0.001
Mean (SD) LA volume index (ml/m2) 27.7 (9.0) 32.6 (10.3) 25.9 (7.8) <0.001
Mean (SD) LVED volume index (ml/m2) 43.8 (14.9) 47.7 (18.1) 42.4 (13.4) 0.002
Diastolic dysfunction grade I 290 (50.5) 141 (89.8) 149 (35.7) <0.001
Diastolic dysfunction grade II 13 (2.3) 11 (7.0) 2 (0.5) <0.001
Diastolic dysfunction grade III 3 (0.5) 3 (1.9) 0 (0.0) 0.005
Values are number (%) unless stated otherwise
a At time of investigation
b Comorbidities mentioned by the patient during history taking
c Prior myocardial infarction, angina pectoris, coronary bypass grafting or percutaneous intervention
d Any abnormality
COPD, chronic obstructive pulmonary disease; LVED, left ventricular end diastolic; TIA, transient ischaemic attack




n HFREF HFPEF All HF n HFREF HFPEF All HF n HFREF HFPEF All HF
60–64 85 3 (3.5) 14 (16.5) 17 (20.0) 60 1 (1.7) 6 (10.0) 7 (11.7) 145 4 (2.8) 20 (13.8) 24 (16.6)
65–69 64 3 (4.7) 10 (15.6) 13 (20.3) 67 2 (3.0) 13 (19.4) 15 (22.4) 131 5 (3.8) 23 (17.6) 28 (21.4)
70–74 65 4 (6.2) 6 (9.2) 10 (15.4) 51 0 (0) 19 (37.3) 19 (37.3) 116 4 (3.4) 25 (21.6) 29 (25)
75–80 49 3 (6.1) 9 (18.4) 12 (24.5) 44 2 (4.5) 20 (45.5) 22 (50.0) 93 5 (5.3) 29 (31.2) 34 (36.6)
≥80 47 7 (14.9) 18 (38.3) 25 (53.2) 49 3 (6.1) 18 (36.7) 21 (42.9) 96 10 (10.4) 36 (37.5) 46 (47.9)
All ages 310 20 (6.8) 57 (18.4) 77 (24.8) 271 8 (3.0) 76 (28.0) 84 (31.0) 581 28 (4.8) 133 (22.9) 161 (27.7)
Values are number (%)
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participants underwent all the diagnostic tests required to
classify heart failure. The use of Doppler tissue imaging
allowed us to measure left ventricular relaxation and filling
pressures, largely independently of load, in a reproducible
and feasible way [24, 25, 27, 32]. Illustrating the good
image quality was the availability of LVEF estimations in
almost all patients (97.5%). Moreover, we aimed to prevent
overdiagnosis of diastolic dysfunction and HFPEF by ap-
plying age-adjusted cut-off values and using strict criteria
for diastolic dysfunction [24, 25]. The use of consensus
diagnosis by an outcome panel is an established method in
case an irreproachable reference standard is lacking, as is the
case for heart failure [33, 34]. Outcome panels have been
successfully used in previous studies on heart failure by our
group [35]. In our study, the reproducibility was high (κ 0.82,
SD 0.08), and comparable to previous studies [5].
The prevalence of previously unknown heart failure in
our study (27.7%) is even higher than reported in patients
aged 65 years and older with chronic obstructive pulmonary
disease [5]. The overall prevalence of heart failure (30.6%)
in our study is about four times higher than expected in
people aged 60 years and older in the general population
[36]. Several previous studies reported a lower prevalence
of heart failure in patients with type 2 diabetes. Bertoni et al
[6] reported 22.3% in patients with an average age of
74 years, with the diagnosis of heart failure based on insur-
ance claims data. Two other studies reported a prevalence of
11.8%, with the diagnosis of heart failure based on heart
failure scores, without the use of echocardiography [7, 9].
Only Davis et al [11] used echocardiography to diagnose
heart failure; however, only the prevalence of HFREF
(7.7%) was assessed, and not HFPEF.
The prevalence of left ventricular dysfunction in our
study, when we include those diagnosed with heart failure,
would be 53.5%: 48.0% diastolic dysfunction and 5.5%
systolic dysfunction. In addition, 11.2% had suboptimal
Table 4 Prevalence of previously unknown systolic and diastolic dysfunction stratified by age and sex in patients with type 2 diabetes aged
≥60 years
Age (years) Male Female Total
n S-Dys D-Dys A-Dys n S-Dys D-Dys A-Dys n S-Dys D-Dys A-Dys
60–64 85 0 28 (32.9) 28 (32.9) 60 0 13 (21.7) 13 (21.7) 145 0 41 (28.3) 41 (28.3)
65–69 64 1 (1.6) 10 (15.6) 11 (17.2) 67 0 20 (29.9) 20 (29.9) 131 1 (0.8) 30 (22.9) 31 (23.6)
70–74 65 2 (3.1) 22 (33.8) 24 (36.9) 51 0 14 (27.5) 14 (27.5) 116 2 (1.7) 36 (31.0) 38 (32.8)
75–80 49 1 (2.0) 15 (30.6) 16 (32.7) 44 0 10 (22.7) 10 (22.7) 93 1 (1.1) 25 (26.9) 21 (28.0)
≥80 47 0 7 (14.9) 7 (14.9) 49 0 7 (14.3) 7 (14.3) 96 0 14 (14.6) 14 (14.6)
All ages 310 4 (1.3) 82 (26.5) 86 (29.0) 271 0 64 (23.6) 64 (23.6) 581 4 (0.7) 146 (25.1) 150 (25.8)
Values are number (%)
A-Dys, all dysfunction; D-Dys, diastolic dysfunction; S-Dys, systolic dysfunction
Table 5 Likely causes of newly
detected heart failure and the
NYHA class, according to the
panel
Values are number (%) unless
stated otherwise. The panel
could adjudicate more than one
possible cause
aAngina pectoris, coronary
artery bypass grafting or percu-
taneous coronary intervention
HF, heart failure
Possible cause/NYHA class HFREF (n028) HFPEF (n0133) All HF (n0161)
Prior myocardial infarction 13 (46.4) 24 (18.0) 37 (23.0)
Other ischaemic heart diseasea 14 (50) 50 (37.6) 64 (39.8)
Hypertension 18 (64.3) 114 (85.7) 132 (82.0)
Hypertension with left ventricular hypertrophy 13 (46.4) 82 (61.7) 95 (59.0)
Atrial fibrillation 2 (7.1) 15 (11.3) 17 (10.6)
Other rhythm and/or conduction disturbances 3 (10.7) 5 (3.8) 8 (5.0)
Valvular disease 8 (28.6) 30 (22.6) 38 (23.6)
Diabetic cardiomyopathy 12 (42.9) 36 (27.1) 48 (29.8)
Chronic obstructive pulmonary disease 5 (17.9) 9 (6.8) 14 (8.7)
Other 3 (10.7) 9 (6.8) 12 (7.5)
NYHA class
II 22 (78.6) 98 (73.7) 120 (74.5)
III 4 (14.3) 35 (26.3) 39 (24.2)
IV 2 (7.1) 0 2 (1.2)
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systolic ventricular dysfunction (LVEF 45–55%). Henry et
al [37] reported high prevalence rates of ventricular dys-
function among older patients with type 2 diabetes, with
similar values for diastolic dysfunction (47%) and a higher
prevalence of systolic dysfunction (30%). Their definition
of systolic dysfunction, namely LVEF≤55% instead of our
definition of LVEF≤45%, is the probable cause of this
higher prevalence.
Screening of patients with type 2 diabetes should be con-
sidered in the light of the high rates of prevalence (27.7%) of
previously unknown heart failure in older patients with type 2
diabetes observed in our study. Physicians should be constant-
ly alert for signs and symptoms indicative of heart failure in
these patients. In addition, echocardiography and/or ECG or
B-type natriuretic peptide measurements could be part of the
yearly monitoring. We need to determine which screening
strategy is the most efficient. Although evidence on how to
optimally treat patients with HFPEF is scarce, there is con-
sensus that at least optimising blood pressure and reducing
heart rate in patients with tachycardia is needed, combined
with optimal treatment of (cardiac) comorbidities [38, 39]. An
annual check for the presence of heart failure in patients with
type 2 diabetes is not yet advised in the diabetes guidelines
[40]. Our results could form the evidence base for such a
recommendation.
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